Skip to main content
. 2022 Mar 8;23(3):381–403. doi: 10.1007/s11864-021-00932-2

Fig. 3.

Fig. 3

Clinical responses to CD19 CAR-NK therapy for CD19 positive lymphoid malignancies. Clinical outcomes of 11 patients treated with cord blood derived, IL-15 expressing, CD19 CAR NK Cell with an inducible caspase 9 suicide gene (iC9/CAR.19/IL-15 CB NK cells). The legend denotes partial response (PR), complete response (CR), minimal residual disease (MRD), and hematopoietic stem cell transplantation (HSCT). Reproduced with permission from: Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545-53. doi: 10.1056/NEJMoa1910607.